RTX001
PreclinicalSmall molecule
RTX001 is one of 21 small molecule programs targeting Liver. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Liver
#DrugCompanyPhaseTrials
1Sunlenca
GileadApproved
Fetroja
ShionogiPhase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Xerava
TTetraphase Pharmaceuticals, Inc
Phase 3
Azactam
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pipracil
WWyeth-Lederle Vaccines
Phase 3
CAZ-AVI
PfizerPhase 3
Aztreonam-Avibactam
PfizerPhase 3
Meropenem-Vaborbactam
MMelinta Therapeutics, Inc.
Phase 3
Imipenem+relebactam
WWake Forest University Health Sciences
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RTX001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RResolution Therapeutics Limited